Results 131 to 140 of about 49,840 (263)

Structural and Mechanistic Insights into Dual Cholinesterase Inhibition by Marine Phytohormones. [PDF]

Mar Drugs
Youn K, Soriano LM, Jun M.
europepmc   +1 more source

Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 1, January/March 2026.
Abstract INTRODUCTION The glucagon‐like peptide‐1 receptor agonist semaglutide may impact neuroinflammation and reduce neurodegeneration. We present baseline characteristics of participants enrolled in the evoke (NCT04777396) and evoke+ (NCT04777409) trials, referred to as “evoke (+)” hereafter.
Philip Scheltens, Alireza Atri, Howard H. Feldman, Henrik Zetterberg, Mary Sano, Peter Johannsen, Teresa León Colombo, Lars Bardtrum, Rose Jeppesen, Charlotte T. Hansen, Jeffrey L. Cummings   +10 more
wiley   +1 more source

Gallic Acid, 3-Hydroxytyrosol, and Quercetin Modulate Cholinesterase Activity in <i>Drosophila melanogaster</i>. [PDF]

Int J Mol Sci
Ucar Akyurek T, Senol Deniz FS, Erdogan Orhan I, Gozuboyuk M, Erdemli GI, Emecen G.   +5 more
europepmc   +1 more source

Experimental and Clinical Studies on the Acetylcholin and Cholinesterase in the Ileus

, 1952
Tadao Suzuki
openalex   +2 more sources

Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 1, January/March 2026.
Abstract INTRODUCTION Escitalopram for Agitation in Alzheimer's Disease (S‐CitAD) is a National Institutes of Health–funded randomized controlled trial that randomized 173 participants with clinically diagnosed Alzheimer's disease (AD) and agitation to escitalopram or placebo for 12 weeks, assessing efficacy and safety.
Maansi Barnwal, Sheriza Baksh, Zahinoor Ismail, David M. Shade, Abhay Moghekar, Sara G. Ho, Paul B. Rosenberg, Anton P. Porsteinsson, Constantine G. Lyketsos, for the S‐CitAD Research Group   +9 more
wiley   +1 more source

Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 1, Page 109-118, January 2026.
In patients with cirrhosis undergoing TIPS, frailty—measured by the Liver Frailty Index—improved in those with poor baseline status; therefore, high frailty should not be seen as a contraindication to elective TIPS. Additionally, LFI assessment before TIPS enables identification of patients with excellent survival prognosis.
Martin Andreas Kabelitz, Simon Johannes Gairing, Anja Tiede, Eva Maria Schleicher, Liv Grete Ahl, Lea Wagner, Falko Zucker‐Reimann, Hannah Rieland, Jim Benjamin Mauz, Julia Weinmann‐Menke, Bernhard C. Meyer, Michael Bernhard Pitton, Heiner Wedemeyer, Peter Robert Galle, Lisa Sandmann, Benjamin Maasoumy, Christian Labenz   +16 more
wiley   +1 more source

Successful management with hemoperfusion and antidotal therapy of severe combined dichlorvos and rodenticide poisoning: a case report. [PDF]

Int J Emerg Med
Li H, Li X, Du B, Yu H, Fu S, Guo Y, Shao H, Chen H, Yang W, Ma L.   +9 more
europepmc   +1 more source

Serum cholinesterase activities before and after therapy of oral cancer

, 1979
Toshio HARADA, Tsugio Inokuchi, Motomasa Sasaki   +2 more
openalex   +2 more sources

Association between CMR‐derived hepatic T1‐time, tricuspid regurgitation and survival

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
We investigated the association between tricuspid regurgitation (TR) severity and hepatic T1‐time in 1029 patients undergoing cardiac MRI and echocardiography. Hepatic T1‐time increased progressively with TR severity and remained independently associated after adjusting for NT‐proBNP and right ventricular function. Both TR and hepatic T1‐time predicted
Katharina Mascherbauer, Christina Kronberger, Manuel Gruber, Carolina Donà, Matthias Koschutnik, Varius Dannenberg, Michael Poledniczek, Laura Lunzer, Christian Nitsche, Franz Duca, Gregor Heitzinger, Kseniya Halavina, Dietrich Beitzke, Christian Loewe, Michael Trauner, Philipp Bartko, Julia Mascherbauer, Christian Hengstenberg, Andreas Kammerlander, Elisabeth Waldmann   +19 more
wiley   +1 more source

From heart to brain: cognitive potential of propranolol and diltiazem through cholinergic enhancement via butyrylcholinesterase inhibition. [PDF]

Front Pharmacol
Domínguez-Fernández C, Kumar A, Kumar R, Darreh-Shori T.   +3 more
europepmc   +1 more source